Dr. Shaji Kumar - Mayo Clinic - Rochester, USA

NCCN 2024 Hematologic Malignancies Congress: Dr. Shaji Kumar To Discuss Advances in Multiple MyelomaПодробнее

HealthTree Podcast for Multiple Myeloma: Dr. Shaji Kumar, Mayo ClinicПодробнее

HealthTree Podcast for Myeloma: Shaji Kumar, MD, Mayo Clinic on ETBs in MyelomaПодробнее

Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma | Meet The Professors Live: Clinical ...Подробнее

Novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclaxПодробнее

Cancer News Interview with Dr. Shaji KumarПодробнее

Disease staging systems in multiple myeloma and how these have evolved over the yearsПодробнее

Smoldering Multiple Myeloma: Is it TREATABLE? | What to know about this RARE CANCERПодробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее

Multiple Myeloma Update | Shaji Kumar, MD | 2022 West Oncology | Updates for APPs & NursesПодробнее

Updates from the BELLINI trialПодробнее

Phase I study of TNB-383B in R/R multiple myelomaПодробнее

First-in-Human Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Pts w/RRMMПодробнее

Shaji Kumar on Recent Clinical Trial Developments in MyelomaПодробнее

Shaji Kumar on the Changing Immunotherapy Landscape in MyelomaПодробнее

International Myeloma Workshop 2021 | Daily Update, Part 1 | Newly Diagnosed + MRDПодробнее

ASH 2020 Updates: CAR T Cell Therapies in Multiple MyelomaПодробнее

ASH 2020 - Highlights in MyelomaПодробнее

Lummicar-2: CT053 for R/R multiple myelomaПодробнее